Skip to main content

Advertisement

Table 3 Treatment characteristics prior to inclusion in the study, 6 months prior to IAI switch, and 6 months after IAI switch

From: Effect of intravitreal aflibercept on recalcitrant diabetic macular edema

# Prior to inclusion in study 6 months prior to IAI switch 6 months after IAI switch
Duration treatment (mo) Total # treatment Type of treatment Total # treatment Type of treatment Total # IAI
l 60 26 6 IVB, 16 IVR, 2 IVTA, 1 STTA, 1 laser 5 5 IVR 4
2 18 10 4 IVB, 4 IVR, 1 IVTA, 1 laser 5 3 IVR, 1 IVTA, 1 laser 6
3 8 5 2 IVB, 3 IVR 4 1 IVB, 3 IVR 5
4 35 30 29 IVB, 1 laser 5 4 IVB, 1 laser 4
5 43 16 7 IVB, 8 IVR, 1 IVTA 5 5 IVR 6
6 9 5 4 IVR, 1 laser 5 4 IVR, 1 laser 4
7 19 16 16 IVR 5 5 IVR 5
B 36 18 6 IVB, 7 IVR, 2 IVTA, 1 dexamethasone intravitreal implant, 2 laser 6 6 IVR 4
9 10 6 4 IVR, 1 IVTA, 1 laser 4 3 IVR, 1 laser 5
10 77 7 5 IVR, 2 laser 4 4 IVR 4
11 33 6 5 IVB, 1 laser 4 4 IVB 5
  Mean = 32 Mean = 13 Mean # anti-VEGF = 11.5 Mean = 4.7 Mean # anti-VEGF = 4.3 Mean = 4.7